The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 120 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 701–800 of 2,716
Reimondo, G., Allasino, B., Bovio, S., Saba, L., Ardito, A., Angeli, A., & Terzolo, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346701 · Cited by 32
Le Marc'hadour, P., Muller, M., Albarel, F., Coulon, A., Morange, I., Martinie, M., Gay, E., Graillon, T., Dufour, H., Conte‐Devolx, B., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12739 · Cited by 25
Reassessing the reliability of the salivary cortisol assay for the diagnosis of Cushing syndrome
Zhang, Q., Dou, J., Gu, W., Yang, G., & Lu, J. (2013) · Journal of International Medical Research · doi:10.1177/0300060513498017 · Cited by 25
“Several studies have shown that saliva samples are well preserved in homerefrigerated conditions, and may be shipped as late as 7 days after being obtained.(17,19,20) Importantly, only the midnight sample can indicate the intactness or loss of diurnal 1388 Journal of International Medical Research 41(5)”
BackgroundPituitary incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.08.006 · Cited by 27
Shrivastava, A., Mohammed, N., Xu, Z., et al. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.01.252 · Cited by 25
Itcho, K., Oki, K., Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., Ohno, H., Kobuke, K., Nagano, G., Yoshii, Y., Baba, R., Hattori, N., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14062 · Cited by 26
Detrimental effects of hypercortisolism on brain structure and related risk factors
Chen, Y., Zhang, J., Tan, H., Li, J., & Yu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-68166-0 · Cited by 29
Melson, E., Davitadze, M., Aftab, M., Ng, C. Y., Ooi, E., Blaggan, P., Chen, W., Hanania, T., Thomas, L., Zhou, D., et al. (2020) · BMC Medical Education · doi:10.1186/s12909-020-02190-6 · Cited by 28
Roldán-Sarmiento, P., Lam-Chung, C. E., Hinojosa-Amaya, J. M., Morales-García, M., Guillén-Placencia, M. F., Pérez-Flores, G. E., León-Suárez, A., León-Domínguez, J., Balbuena-Álvarez, S., Nava de la Vega, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa774 · Cited by 25
Day-to-day variation of late-night salivary cortisol in healthy voluntaries
Casals, G., Foj, L., & de Osaba, M. J. M. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.02.003 · Cited by 27
Cyclic Cushing syndrome due to an ectopic pituitary adenoma
Zerikly, R. K., Eray, E., Faiman, C., et al. (2008) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1039 · Cited by 25
Glucocorticoid receptor haplotype and metabolic syndrome: the Lifelines cohort study
Wester, V. L., Koper, J. W., van den Akker, E. L. T., Franco, O. H., Stolk, R. P., & van Rossum, E. F. C. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0534 · Cited by 24
Araujo-Castro, M., García Cano, A., Jiménez Mendiguchía, L., Escobar-Morreale, H. F., & Valderrábano, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00011-4 · Cited by 24
Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements
Stieglitz, H. M., Korpi-Steiner, N. L., Katzman, B. M., Mersereau, J. E., & Styner, M. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00069 · Cited by 26
“A low-dose dexamethasone suppression test revealed incomplete suppression of cortisol (26 mg/dL) [2], though the measured dexamethasone level was 44 ng/dL (expected 140 to 295 ng/dL after 1mg dexamethasone), suggesting potential incomplete absorption.”
BackgroundComputer Vision Technology in the Differential Diagnosis of Cushing’s Syndrome
Popp, K. H., Kosilek, R. P., FROHNER, R. N., Stalla, G. K., Athanasoulia-Kaspar, A. P., Berr, C., Zopp, S., Reincke, M., Witt, M., Würtz, R. P., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0887-4233 · Cited by 27
“Many clinical and biochemical features of CS are unspecific and can also be found in patients suffering from the metabolic syn - drome (MetS) which consists of abdominal obesity, hypertension, impaired glucose metabolism and dyslipidemia [1, 8].”
BackgroundWang, F., Catalino, M. P., Bi, W. L., Dunn, I. F., Smith, T. R., Guo, Y., Hordejuk, D., Kaiser, U. B., Laws, E. R., & Min, L. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa773 · Cited by 32
Belaya, Z. E., Golounina, O. O., Mel'nichenko, G. A., Tarbaeva, N. V., Pashkova, E., Gorokhov, M., Kalashnikov, V., Dzeranova, L. K., Fadeev, V. V., Volchkov, P., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02674-5 · Cited by 24
Prolactin and Other Pituitary Disorders in Kidney Disease
Huang, W., & Molitch, M. E. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.010 · Cited by 33
Qualitative and Quantitative Mass Spectrometry in Salivary Metabolomics and Proteomics
Grocholska, P., Kowalska, M., & Bąchor, R. (2023) · Metabolites · doi:10.3390/metabo13020155 · Cited by 36
Ospina, N. S., Rodríguez‐Gutiérrez, R., Brito, J. P., Young, W. F., & Montori, V. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0435-z · Cited by 28
“Using the ES guideline web site, we identified and retrieved all ES clinical practice guidelines issued from 2008 to 2014 [13–38].”
MethodSelf-citationMurasawa, S., Kageyama, K., Sugiyama, A., Ishigame, N., Niioka, K., Suda, T., & Daimon, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.001 · Cited by 25
“Cushing’s disease is primarily caused by ACTH-producing pituitary adenomas (Nieman et al., 2008; Kageyama et al., 2013).”
Endocrine hypertension — Current understanding and comprehensive management review
Sukor, N. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.05.004 · Cited by 26
“The Endocrine Society Clinical Practice Guideline [47] recommends testing for Cushing's syndrome in the following group: • Patientswith unusual features for age (e.g. hypertension, osteoporosis) • Patients with progressive features of Cushing's syndrome • Children with low height percentile and increasing weight • Pat…”
MethodInfluentialA patient with ectopic cortisol production derived from malignant testicular masses
Jain, S. H., Sadow, P. M., Nosé, V., & Dluhy, R. G. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0985 · Cited by 26
Willenberg, H. S., Späth, M. R., Maser‐Gluth, C., Engers, R., Anlauf, M., Dekomien, G., Schott, M., Schinner, S., Cupisti, K., & Scherbaum, W. A. (2010) · Hypertension Research · doi:10.1038/hr.2010.18 · Cited by 27
Clinical use of pasireotide for Cushing's disease in adults
Boscaro, M., Ceccato, F., & Scaroni, C. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37314 · Cited by 36
“The latter case applies to the condition known as Cushing’s disease (CD), which accounts for about 70% of cases of endogenous chronic hypercortisolism.(1,2) CS is rare, and patients may present with several characteristic signs or symptoms or with a by-no-means-clear clinical picture, and sometimes only isolated signs.”
BackgroundMethodSurgical remission of Cushing's syndrome reduces cardiovascular risk
Terzolo, M., Allasino, B., Pia, A., Peraga, G., Daffara, F., Laino, F., Ardito, A., Termine, A., Paccotti, P., Berchialla, P., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0555 · Cited by 23
Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea
Hur, K. Y., Kim, J. H., Kim, B.-J., Kim, M., Lee, E. J., & Kim, S.-W. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.7 · Cited by 24
Adrenal incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.07.017 · Cited by 28
Steffensen, C., Dekkers, O. M., Lyhne, J. D., Pedersen, B. G., Rasmussen, F., Rungby, J., Poulsen, P. L., & Jørgensen, J. O. L. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0809-3647 · Cited by 28
“In accordance with this, current guidelines recommend against wide spread testing for Cushing’s syndrome [34] and against considering ‘autonomous cortisol secretion’ a condition with a high risk for developing Cushing’s syndrome [37].”
MethodDietary sodium intake and cortisol measurements
Chen, A. X., Haas, A. V., Williams, G. H., & Vaidya, A. (2020) · Clinical Endocrinology · doi:10.1111/cen.14262 · Cited by 23
Castro, M. A., Corrales, E. P., Millán, J. M. S., Rebolleda, G., Pian, H. G., Ruz‐Caracuel, I., Santos, G. D. L., Urzaiz, L. L., Escobar-Morreale, H. F., & Berrocal, V. R. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.11.001 · Cited by 26
Basic endocrinological disorders in chronic renal failure.
Niemczyk, S., Niemczyk, L., & Romejko, K. (2012) · PubMed · Cited by 38
Adrenal reserve function after unilateral adrenalectomy in patients with primary aldosteronism
Honda, K., Sone, M., Tamura, N., Sonoyama, T., Taura, D., Kojima, K., Fukuda, Y., Tanaka, S., Yasuno, S., Fujii, T., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283635789 · Cited by 27
The Role of Cortisol in the Pathogenesis of the Metabolic Syndrome
Jeong, I. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.3.207 · Cited by 27
“Previous studies have evaluated the association between MetS and hypercortisolism by examining fasting plasma cortisol, 24-hour urinary free cortisol, cortisol reactivity to some stimuli, or profiles of cortisol patterns over the day [8-24].”
BackgroundEmerging diagnostic methods and imaging modalities in cushing’s syndrome
Wright, K. E., van Rossum, E. F. C., Zan, E., Werner, N. L., Harris, A. G., Feelders, R. A., & Agrawal, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230447 · Cited by 33
“UFC levels modestly increase in the second and third trimester and, although UFC levels of more than 3 times the upper limit of normal (ULN) are indicative of CS, it can be difficult to distinguish CS from physiological activation of the HPA-axis when UFC levels are mildly elevated (11, 28).”
BackgroundMethodEvaluation of patients with adrenal incidentalomas
Kannan, S., Remer, E. M., & Hamrahian, A. H. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328360a43b · Cited by 24
“SCS is associated with high prevalence of metabolic complications including obesity, hypertension, and hyperglycemia [45–47,48 & ,49,50].”
InfluentialMinetto, M. A., Caresio, C., Salvi, M., D’Angelo, V., Gorji, N. E., Molinari, F., Arnaldi, G., Kesari, S., & Arvat, E. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0979-9 · Cited by 27
Tapia-Castillo, A., Guanzon, D., Palma, C., Lai, A., Barros, E., Allende, F. A., Vecchiola, A., Fardella, C., Salomón, C., & Carvajal, C. A. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02143-8 · Cited by 24
Lee, C., Kim, J. H., Moon, S. J., Shim, J., Kim, H. I., & Choi, M. H. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105615 · Cited by 23
Dai, C., Feng, M., Sun, B., Bao, X., Yao, Y., Deng, K., Ren, Z.-Y., Zhao, B., Lü, L., Wang, R., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02848-1 · Cited by 24
Pivonello, R., Münster, P. N., Terzolo, M., Ferrigno, R., Simeoli, C., Puglisi, S., Bali, U., & Moraitis, A. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.793262 · Cited by 30
Exogenous Cushing Syndrome Caused by a “Herbal” Supplement
Patel, R., Sherf, S., Lai, N. B., & Yu, R. (2022) · AACE Clinical Case Reports · doi:10.1016/j.aace.2022.08.001 · Cited by 23
Cancela, A. A., Berrocal, V. R., Arias, H. P., Díez, J. J., & Iglesias, P. (2022) · Endocrine · doi:10.1007/s12020-022-03161-1 · Cited by 25
Cushing′s syndrome: Stepwise approach to diagnosis
Lila, A. R., Sarathi, V., Jagtap, V., Bandgar, T., Menon, P. S. N., & Shah, N. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.86974 · Cited by 27
“Specific manifestations of hypercortisolism are those affecting skin (livid striae and ecchymoses), muscle (proximal myopathy) and bone (short stature in an obese child, vertebral compression fractures).[1] These catabolic manifestations are subtle in the early course of the disease and manifest with long standing and…”
BackgroundMethodBassareo, P. P., Marras, A. R., Pasqualucci, D., & Mercuro, G. (2010) · Cardiology in the Young · doi:10.1017/s1047951110000727 · Cited by 24
Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells
Sugiyama, A., Kageyama, K., Murasawa, S., Ishigame, N., Niioka, K., & Daimon, M. (2014) · Pituitary · doi:10.1007/s11102-014-0607-4 · Cited by 24
Rotation thromboelastometry and the hypercoagulable state in C ushing's syndrome
Coelho, M. C. A., Neto, L. V., Kasuki, L., Wildemberg, L. E., dos Santos, C. V., Castro, G., Gouvêa, G., Veloso, O. C. G., Gadelha, T., & Gadelha, M. R. (2014) · Clinical Endocrinology · doi:10.1111/cen.12491 · Cited by 27
Roerink, S. H. P. P., Wagenmakers, M. A. E. M., Smit, J. W. A., van Rossum, E. F. C., Netea-Maier, R. T., Plantinga, T. S., & Hermus, A. R. M. M. (2016) · Endocrine · doi:10.1007/s12020-016-0883-z · Cited by 27
Jiang, H., He, N., Sun, Y., Jian, F., Bian, L., Shen, J.-K., Yan, F., Pan, S., & Sun, Q. (2017) · Brain Research · doi:10.1016/j.brainres.2017.04.007 · Cited by 26
Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome
Perez‐Rivas, L. G., Oßwald, A., Knösel, T., Lucia, K. E., Schaaf, C. P., Hristov, M., Fazel, J., Kirchner, T., Beuschlein, F., Reincke, M., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0054 · Cited by 23
Yoshida, K., Fukuoka, H., Odake, Y., Nakajima, S., Tachibana, M., Ito, J., Hosokawa, Y., Yamada, T., Miura, H., Suematsu, N., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00375 · Cited by 23
Wu, C., Zhang, H., Zhang, J., Zhang, H., Zeng, Y., Fang, S., Li, P., Zhang, Y., Lin, X., Wang, L., et al. (2019) · Adipocyte · doi:10.1080/21623945.2019.1690834 · Cited by 24
“The diagnosis of Cushing’s syndrome was made according to guidelines [8].”
MethodUSP8 Mutations and Cell Cycle Regulation in Corticotroph Adenomas
Martins, C. S., Camargo, R. C., Coeli‐Lacchini, F. B., Saggioro, F. P., Moreira, A. C., & de Castro, M. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1089-7806 · Cited by 24
“Cushingʼs syndrome diagnosis was established on clinical assessment and biochemical evidence of hypercortisolism, according to international criteria [29].”
MethodCushing syndrome: Old and new genes
Tatsi, C., Flippo, C. L., & Stratakis, C. A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101418 · Cited by 47
Radiology report language positively influences adrenal incidentaloma guideline adherence
Watari, J., Vekaria, S., Lin, Y., Patel, M., Kim, H., Kang, F., Lubitz, S. E., Beninato, T., & Laird, A. M. (2021) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2021.06.015 · Cited by 27
Oki, Y., Hashimoto, K., Hirata, Y., Iwasaki, Y., Nigawara, T., Doi, M., Sakihara, S., Kageyama, K., & Suda, T. (2009) · Endocrine Journal · doi:10.1507/endocrj.k09e-194 · Cited by 28
Perioperative management of patients undergoing transsphenoidal pituitary surgery.
Zada, G., Woodmansee, W. W., Iuliano, S., & Laws, E. R. (2010) · PubMed Central · Cited by 26
Adrenal cavernous hemangioma with subclinical Cushing’s syndrome: report of a case
Oishi, M., Ueda, S., Honjo, S., Koshiyama, H., Yuba, Y., & Takabayashi, A. (2012) · Surgery Today · doi:10.1007/s00595-012-0203-z · Cited by 25
“The gold standard for diagnosis has not been defined, but blunt circadian rhythms of cortisol and suppressed ACTH level are highly indicative of the disease [9, 10].”
BackgroundEndocrine hypertension - Cushing′s syndrome
Singh, Y., Kotwal, N., & Menon, A. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.86973 · Cited by 23
Machado, M. C., Fragoso, M. C. B. V., Moreira, A. C., Boguszewski, C. L., Vieira Neto, L., Naves, L. A., Vilar, L., Araújo, L. A. D., Czepielewski, M. A., Gadelha, M. R., et al. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000174 · Cited by 21
“Thus, it is important to look for more specific signs of Cushing’s syndrome, such as facial plethora, proximal muscle weakness, large (> 1 cm) and reddish/violet skin striae and spontaneous ecchymosis in patients presenting weight gain (27,28) (Table 2).”
BackgroundMethodInfluentialPolycystic ovary syndrome: Recent research and therapeutic advancements
Dilliyappan, S., Kumar, A. S., Venkatesalu, S., Palaniyandi, T., Baskar, G., Sivaji, A., Rab, S. O., Saeed, M., & Shivaranjani, K. S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123221 · Cited by 29
Discovery of Cushing’s Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients
Javorsky, B. R., Carroll, T. B., Tritos, N. A., Salvatori, R., Heaney, A. P., Fleseriu, M., Biller, B. M. K., & Findling, J. W. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1681-z · Cited by 23
“The diagnosis of CS was made based on clinical features (no patients had subclinical CS), abnormal late-night salivary cortisol, overnight low-dose dexamethasone suppression test, and/or 24-h urine free cortisol (UFC) as defined in the Endocrine Society clinical guideline for the diagnosis of CS [5] (Table 1).”
BackgroundMethodInfluentialSelf-citationHong, N., Lee, J., Ku, C. R., Han, K., Lee, C. R., Kang, S., & Rhee, Y. (2018) · Clinical Endocrinology · doi:10.1111/cen.13902 · Cited by 24
Chiodini, I., Gaudio, A., Eller-Vainicher, C., Morelli, V., Aresta, C., Zhukouskaya, V. V., Merlotti, D., Orsi, E., Barbieri, A. M., Fustinoni, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00037 · Cited by 24
Management of adrenal incidentalomas: Working through uncertainty
Cambos, S., & Tabarin, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101427 · Cited by 28
Wurth, R., Tirosh, A., Kamilaris, C. D. C., Camacho, J., Faucz, F. R., Maria, A. G., Berthon, A. S., Papadakis, G. Z., Nilubol, N., Hamimi, A., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa162 · Cited by 26
“Subjects were initially examined for clinical features of CS, with subsequent biochemical confirmation when 2 or more of the following screening tests were consistent with hypercortisolemia: 24-hour urinary free cortisol (UFC), midnight serum cortisol, and the low-dose dexamethasone suppression test [20].”
MethodInfluentialŠojat, A. S., Dunjić-Kostić, B., Marina, L., Ivović, M., Radonjić, N. V., Kendereški, A., Cirkovic, A. M., Tančić‐Gajić, M., Arizanović, Z., Mihajlovic, S., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01509-4 · Cited by 30
Castro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.08.010 · Cited by 27
“) and clearly pathological urinary free cortisol (UFC) values.(38) However, the diagnosis of ACS constitutes the greatest diagnostic challenge in patients with AI, given the lack of consensus on its definition and the cut-off points used in the different screening tests.”
BackgroundMethodSecond-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism
Pinelli, S., Barbot, M., Scaroni, C. M., & Ceccato, F. (2021) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.6.521 · Cited by 26
“Endogenous Cushing’s syndrome (CS) is caused by excessive and unregulated cortisol secretion [1, 2].”
BackgroundTritos, N. A., Fazeli, P. K., McCormack, A. I., Mallea-Gil, S., Pineyro, M. M., Christ‐Crain, M., Frara, S., Labadzhyan, A., Ioachimescu, A. G., Shimon, I., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01170-3 · Cited by 23
Alba, E. L., Japp, E., Fernandez-Ranvier, G. G., Badani, K. K., Wilck, E. J., Ghesani, M. V., Wolf, A., Wolin, E. M., Corbett, V., Steinmetz, D., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac073 · Cited by 26
“Adding corticotrophinreleasing hormone (CRH) and desmopressin stimulation testing to HDDST increases the sensitivity of localization [7].”
BackgroundCastro, M. A., & Marazuela, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.913253 · Cited by 29
Bellastella, G., Maiorino, M. I., Bellis, A. D., Vietri, M. T., Mosca, C., Scappaticcio, L., Pasquali, D., Esposito, K., & Giugliano, D. (2015) · Endocrine · doi:10.1007/s12020-015-0777-5 · Cited by 22
Age and the metabolic syndrome affect salivary Cortisol rhythm: data from a community sample
Ceccato, F., Barbot, M., Zilio, M., Ferasin, S., Lazzari, P. D., Lizzul, L., Boscaro, M., & Scaroni, C. M. (2015) · HORMONES · doi:10.14310/horm.2002.1591 · Cited by 24
Pasireotide for the treatment of Cushing's disease
Arnaldi, G., & Boscaro, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.495943 · Cited by 23
“Clinical manifestations of Cushing’s disease include weight gain, truncal obesity with supraclavicular fat accumulation and cervical fat pad, thinned skin, purple striae, severe fatigue, muscle weakness, hypertension, diabetes, hypercoagulability, acne, hirsutism and menstrual disorders, osteoporosis, and neuropsychol…”
BackgroundTrementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Polenta, B., Spinello, M., Boscaro, M., & Arnaldi, G. (2014) · Pituitary · doi:10.1007/s11102-014-0557-x · Cited by 23
Chandran, D. S., Ali, N., Jaryal, A. K., Jyotsna, V. P., & Deepak, K. K. (2012) · Neuroendocrinology · doi:10.1159/000345905 · Cited by 26
The functional status of incidentally discovered bilateral adrenal lesions
Androulakis, I. I., Kaltsas, G. A., Markou, A., Tseniklidi, E., Kafritsa, P., Pappa, T., Papanastasiou, L., & Piaditis, G. P. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04013.x · Cited by 22
Costa, D., Conceição, F. L., Leite, N. C., Ferreira, M. T., Salles, G. F., & Cardoso, C. R. L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.006 · Cited by 26
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?
Piantanida, E., Gallo, D., Veronesi, G., Dozio, E., Trotti, E., Lai, A., Ippolito, S., Sabatino, J., Tanda, M. L., Toniolo, A., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0304 · Cited by 29
Grasso, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0288-6 · Cited by 24
Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms
Guilmette, J. M., & Nosé, V. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.03.002 · Cited by 27
Assessment of non-traumatic vertebral fractures in Cushing’s syndrome patients
Apaydın, T., & Yavuz, D. G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01496-y · Cited by 25
Characterization of cyclic Cushing's disease using late night salivary cortisol testing
Jahandideh, D., Swearingen, B., Nachtigall, L. B., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13758 · Cited by 21
Self-citationUse of salivary cortisol and cortisone in the high- and low-dose synacthen test
Elder, C. J., Harrison, R. F., Cross, A. S., Vilela, R., Keevil, B. G., Wright, N. P., & Ross, R. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13509 · Cited by 21
Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL
Martel‐Duguech, L., Alonso‐Jiménez, A., Bascuñana, H., Díaz‐Manera, J., Llauger, J., Nuñez‐Peralta, C., Montesinos, P., Webb, S. M., & Valassi, E. (2021) · Clinical Endocrinology · doi:10.1111/cen.14568 · Cited by 25
“According to the criteria established based on internationally agreed guidelines, diagnosis of CS was made after clinical, biochemical and radiological evaluation.(15) Twenty‐eight patients had Cushing's disease (CD) due to a pituitary microadenoma (n=25) or a macroadenoma (n=3).”
MethodMetabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Ku, E. J., Lee, C., Shim, J., Lee, S., Kim, K., Kim, S. W., Rhee, Y., Kim, H., Lim, J. S., Chung, C. H., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1149 · Cited by 22
“These findings may implicate an increase in overall glucocorticoid precursors and metabolites in subjects with CS, which is in accordance with a recent study regarding the diagnosis of CS [20].”
ResultFerrière, A., & Tabarin, A. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104091 · Cited by 21
Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation
Guarnotta, V., Gaudio, F. D., & Giordano, C. S. D. S. (2022) · Nutrients · doi:10.3390/nu14050973 · Cited by 25
“Clinical practice guidelines and a recent consensus statement were used to diagnose CD [31,32].”
MethodNakao, H., Yokomoto‐Umakoshi, M., Nakatani, K., Umakoshi, H., Ogata, M., Fukumoto, T., Kaneko, H., Iwahashi, N., Fujita, M., Ogasawara, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104733 · Cited by 25
Delineating endogenous Cushing’s syndrome by GC-MS urinary steroid metabotyping
Braun, L., Oßwald, A., Zopp, S., Rubinstein, G., Vogel, F., Riester, A., Honegger, J. B., Eisenhofer, G., Constantinescu, G. A., Deutschbein, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104907 · Cited by 21
“According to diagnostic guidelines and a current consensus, 20,21 at least two of the following three tests have to show abnormal results in order to diagnose CS: the 1 mg-low-dose-dexamethasone-suppression-test, the late-night salivary cortisol concentration and the urinary excretion of free…”
MethodImage-Guided Ablation of Adrenal Tumors
Ethier, M., Beland, M. D., & Mayo-Smith, W. W. (2013) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2013.08.008 · Cited by 22
Coactivation of SF-1-Mediated Transcription of Steroidogenic Enzymes by Ubc9 and PIAS1
Suda, N., Shibata, H., Kurihara, I., Ikeda, Y., Kobayashi, S., Yokota, K., Murai‐Takeda, A., Nakagawa, K., Oya, M., Murai, M., et al. (2011) · Endocrinology · doi:10.1210/en.2010-1232 · Cited by 22
Luteinizing hormone correlates with adrenal function in postmenopausal women
Saxena, A. R., & Seely, E. W. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31825540c4 · Cited by 21
“Measurements of UFC and AER provide integrated assessment of cortisol and aldosterone secretion over a 24-hour period and are superior to single serum measurements of cortisol and aldosterone in diagnosing cortisol or aldosterone excess.(8,9) Our study was able to detect a relationship of LH with cortisol and aldoster…”
BackgroundFGFR4 Polymorphic Variants Modulate Phenotypic Features of Cushing Disease
Nakano-Tateno, T., Tateno, T., Hlaing, M. M., Zheng, L., Yoshimoto, K., Yamada, S., Asa, S. L., & Ezzat, S. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1412 · Cited by 22
Camozzi, V., Sanguin, F., Albigier, N., Scaroni, C. M., Mantero, F., Zaninotto, M., Frigo, A., Piccolo, M., & Luisetto, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0800 · Cited by 25
Performance of the 1 mg dexamethasone suppression test in patients with severe obesity
Lammert, A., Nittka, S., Otto, M., Schneider‐Lindner, V., Kemmer, A., Krämer, B. K., Birck, R., Hammes, H., & Benck, U. (2016) · Obesity · doi:10.1002/oby.21442 · Cited by 25
“In patients with CYP3A4 inducers and/or estrogen therapy, DST should not be used for screening for hypercortisolism (5).”
BackgroundInfluentialAranda, G. B., Fernandez‐Ruiz, R., Palomo, M., Romo, M., Mora, M., Halperín, I., Casals, G., Enseñat, J., Vidal, Ó., Díaz‐Ricart, M., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13521 · Cited by 24
Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome
Wannachalee, T., Turcu, A. F., & Auchus, R. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13818 · Cited by 22
Ceylan, S., Anık, İ., Çabuk, B., et al. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.04.013 · Cited by 21
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.